|
1.
|
Barth BM, Shanmugavelandy SS, Kaiser JM, McGovern C, Altinoglu EI, Haakenson JK, Hengst JA, Gilius EL, Knupp SA, Fox TE, Smith JP, Ritty TM, Adair JH, Kester M. PhotoImmunoNanoTherapy Reveals an Anticancer Role for Sphingosine Kinase 2 and Dihydrosphingosine-1-Phosphate. ACS Nano. 2013 Mar 26; 7(3):2132-44.
|
|
|
|
|
2.
|
Morad SA, Madigan JP, Levin JC, Abdelmageed N, Karimi R, Rosenberg DW, Kester M, Shanmugavelandy SS, Cabot MC. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol. 2013 Apr 15; 85(8):1057-65.
|
|
|
|
|
3.
|
Barth BM, Shanmugavelandy SS, Tacelosky DM, Kester M, Morad SA, Cabot MC. Gaucher's Disease and Cancer: A Sphingolipid Perspective. Crit Rev Oncog. 2013; 18(3):221-34.
|
|
|
|
|
4.
|
Hankins JL, Doshi UA, Haakenson JK, Young MM, Barth BM, Kester M. The therapeutic potential of nanoscale sphingolipid technologies. Handb Exp Pharmacol. 2013; 215:197-210.
|
|
|
|
|
5.
|
Young MM, Kester M, Wang HG. Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res. 2013 Jan; 54(1):5-19.
|
|
|
|
|
6.
|
Fox TE, Young MM, Pedersen MM, Han X, Gardner TW, Kester M. Diabetes Diminishes Phosphatidic Acid in the Retina: A Putative Mediator for Reduced mTOR Signaling and Increased Neuronal Cell Death. Invest Ophthalmol Vis Sci. 2012; 53(11):7257-67.
|
|
|
|
|
7.
|
Morad SA, Levin JC, Shanmugavelandy SS, Kester M, Fabrias G, Bedia C, Cabot MC. Ceramide-antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2352-61.
|
|
|
|
|
8.
|
Tacelosky DM, Creecy AE, Shanmugavelandy SS, Smith JP, Claxton DF, Adair JH, Kester M, Barth BM. Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer. Discov Med. 2012 Apr; 13(71):275-85.
|
|
|
|
|
9.
|
Kaiser JM, Imai H, Haakenson JK, Brucklacher RM, Fox TE, Shanmugavelandy SS, Unrath KA, Pedersen MM, Dai P, Freeman WM, Bronson SK, Gardner TW, Kester M. Nanoliposomal minocycline for ocular drug delivery. Nanomedicine. 2013 Jan; 9(1):130-40.
|
|
|
|
|
10.
|
Young MM, Takahashi Y, Khan O, Park S, Hori T, Yun J, Sharma AK, Amin S, Hu CD, Zhang J, Kester M, Wang HG. Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem. 2012 Apr 6; 287(15):12455-68.
|
|
|
|
|
11.
|
Watters RJ, Kester M, Tran MA, Loughran TP, Liu X. Development and use of ceramide nanoliposomes in cancer. Methods Enzymol. 2012; 508:89-108.
|
|
|
|
|
12.
|
Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, Staveley-O'Carroll KF. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology. 2012 Jan; 55(1):141-52.
|
|
|
|
|
13.
|
Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M. Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression. J Biol Chem. 2011 Dec 30; 286(52):44357-66.
|
|
|
|
|
14.
|
Barth BM, Cabot MC, Kester M. Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med Chem. 2011 Nov; 11(9):911-9.
|
|
|
|
|
15.
|
Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother. 2011 Nov; 45(11):1399-405.
|
|
|
|
|
16.
|
Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biol Ther. 2011 Oct 1; 12(7):574-85.
|
|
|
|
|
17.
|
Tabakovic A, Kester M, Adair JH. Calcium phosphate-based composite nanoparticles in bioimaging and therapeutic delivery applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012 Jan-Feb; 4(1):96-112.
|
|
|
|
|
18.
|
Heakal Y, Woll MP, Fox T, Seaton K, Levenson R, Kester M. Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains. Cancer Biol Ther. 2011 Sep 1; 12(5):427-35.
|
|
|
|
|
19.
|
Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, Jarbadan NR, Baab KT, Liao J, Wang HG, Kester M, Desai D, Amin S, Loughran TP, Liu X. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011 Sep 8; 118(10):2793-800.
|
|
|
|
|
20.
|
Barth BM, I Altinoglu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP, Claxton DF, Kester M. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano. 2011 Jul 26; 5(7):5325-37.
|
|
|
|
|
21.
|
O'Neill SM, Yun JK, Fox TE, Kester M. Transcriptional regulation of the human neutral ceramidase gene. Arch Biochem Biophys. 2011 Jul; 511(1-2):21-30.
|
|
|
|
|
22.
|
O'Neill SM, Houck KL, Yun JK, Fox TE, Kester M. AP-1 binding transcriptionally regulates human neutral ceramidase. Arch Biochem Biophys. 2011 Jul; 511(1-2):31-9.
|
|
|
|
|
23.
|
Ryland LK, Fox TE, Liu X, Loughran TP, Kester M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther. 2011 Jan 15; 11(2):138-49.
|
|
|
|
|
24.
|
Fox TE, Young MM, Pedersen MM, Giambuzzi-Tussey S, Kester M, Gardner TW. Insulin signaling in retinal neurons is regulated within cholesterol-enriched membrane microdomains. Am J Physiol Endocrinol Metab. 2011 Mar; 300(3):E600-9.
|
|
|
|
|
25.
|
Takahashi Y, Meyerkord CL, Hori T, Runkle K, Fox TE, Kester M, Loughran TP, Wang HG. Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy. 2011 Jan; 7(1):61-73.
|
|
|
|
|
26.
|
Tagaram HR, Divittore NA, Barth BM, Kaiser JM, Avella D, Kimchi ET, Jiang Y, Isom HC, Kester M, Staveley-O'Carroll KF. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut. 2011 May; 60(5):695-701.
|
|
|
|
|
27.
|
Barth BM, Gustafson SJ, Young MM, Fox TE, Shanmugavelandy SS, Kaiser JM, Cabot MC, Kester M, Kuhn TB. Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance. Cancer Biol Ther. 2010 Dec 1; 10(11):1126-36.
|
|
|
|
|
28.
|
Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, Jefferson LS, Kim JK, Bronson SK, Flanagan JM, Kester M. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res. 2011 Mar; 52(3):509-17.
|
|
|
|
|
29.
|
Adair JH, Parette MP, Altinoglu EI, Kester M. Nanoparticulate alternatives for drug delivery. ACS Nano. 2010 Sep 28; 4(9):4967-70.
|
|
|
|
|
30.
|
Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood. 2010 Nov 18; 116(20):4192-201.
|
|
|
|
|
31.
|
Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR. Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am J Physiol Cell Physiol. 2010 Aug; 299(2):C335-44.
|
|
|
|
|
32.
|
Chapman JV, Gouazé-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, Barth BM, Liu X, Liu YY, Giuliano AE, Cabot MC. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches. Biochem Pharmacol. 2010 Aug 1; 80(3):308-15.
|
|
|
|
|
33.
|
Ganapathi SB, Fox TE, Kester M, Elmslie KS. Ceramide modulates HERG potassium channel gating by translocation into lipid rafts. Am J Physiol Cell Physiol. 2010 Jul; 299(1):C74-86.
|
|
|
|
|
34.
|
Barth BM, Sharma R, Altinoglu EI, Morgan TT, Shanmugavelandy SS, Kaiser JM, McGovern C, Matters GL, Smith JP, Kester M, Adair JH. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano. 2010 Mar 23; 4(3):1279-87.
|
|
|
|
|
35.
|
Fox TE, Kester M. Therapeutic strategies for diabetes and complications: a role for sphingolipids? Adv Exp Med Biol. 2010; 688:206-16.
|
|
|
|
|
36.
|
Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther. 2009 Oct; 8(19):1831-7.
|
|
|
|
|
37.
|
Wijesinghe DS, Allegood JC, Gentile LB, Fox TE, Kester M, Chalfant CE. Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. J Lipid Res. 2010 Mar; 51(3):641-51.
|
|
|
|
|
38.
|
Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester M, Smith JP. Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression. Pancreas. 2009 Jul; 38(5):e151-61.
|
|
|
|
|
39.
|
Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells. Mol Cancer Res. 2009 May; 7(5):724-34.
|
|
|
|
|
40.
|
Ganapathi SB, Kester M, Elmslie KS. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol. 2009 Apr; 296(4):C701-10.
|
|
|
|
|
41.
|
Salli U, Fox TE, Carkaci-Salli N, Sharma A, Robertson GP, Kester M, Vrana KE. Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells Dev. 2009 Jan-Feb; 18(1):55-65.
|
|
|
|
|
42.
|
Morgan TT, Muddana HS, Altinoglu EI, Rouse SM, Tabakovic A, Tabouillot T, Russin TJ, Shanmugavelandy SS, Butler PJ, Eklund PC, Yun JK, Kester M, Adair JH. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Lett. 2008 Dec; 8(12):4108-15.
|
|
|
|
|
43.
|
Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, Altinoglu EI, Tabakovic A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Lett. 2008 Dec; 8(12):4116-21.
|
|
|
|
|
44.
|
Abcouwer SF, Shanmugam S, Gomez PF, Shushanov S, Barber AJ, Lanoue KF, Quinn PG, Kester M, Gardner TW. Effect of IL-1beta on survival and energy metabolism of R28 and RGC-5 retinal neurons. Invest Ophthalmol Vis Sci. 2008 Dec; 49(12):5581-92.
|
|
|
|
|
45.
|
Altinoglu EI, Russin TJ, Kaiser JM, Barth BM, Eklund PC, Kester M, Adair JH. Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano. 2008 Oct 28; 2(10):2075-84.
|
|
|
|
|
46.
|
Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 2008 Sep 15; 68(18):7638-49.
|
|
|
|
|
47.
|
Houck KL, Fox TE, Sandirasegarane L, Kester M. Ether-linked diglycerides inhibit vascular smooth muscle cell growth via decreased MAPK and PI3K/Akt signaling. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1657-68.
|
|
|
|
|
48.
|
Pearlman E, Johnson A, Adhikary G, Sun Y, Chinnery HR, Fox T, Kester M, McMenamin PG. Toll-like receptors at the ocular surface. Ocul Surf. 2008 Jul; 6(3):108-16.
|
|
|
|
|
49.
|
Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res. 2008 Jun 1; 14(11):3571-81.
|
|
|
|
|
50.
|
Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab Dispos. 2008 Aug; 36(8):1709-15.
|
|
|
|
|
51.
|
Sun Y, Fox T, Adhikary G, Kester M, Pearlman E. Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol. 2008 Jun; 83(6):1512-21.
|
|
|
|
|
52.
|
Stover TC, Kim YS, Lowe TL, Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials. 2008 Jan; 29(3):359-69.
|
|
|
|
|
53.
|
Fox TE, Houck KL, O'Neill SM, Nagarajan M, Stover TC, Pomianowski PT, Unal O, Yun JK, Naides SJ, Kester M. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. J Biol Chem. 2007 Apr 27; 282(17):12450-7.
|
|
|
|
|
54.
|
Fox TE, Han X, Kelly S, Merrill AH, Martin RE, Anderson RE, Gardner TW, Kester M. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes. 2006 Dec; 55(12):3573-80.
|
|
|
|
|
55.
|
Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006 Sep; 55(9):2401-11.
|
|
|
|
|
56.
|
Fox TE, Finnegan CM, Blumenthal R, Kester M. The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci. 2006 May; 63(9):1017-23.
|
|
|
|
|
57.
|
Basile M, Lin R, Kabbani N, Karpa K, Kilimann M, Simpson I, Kester M. Paralemmin interacts with D3 dopamine receptors: implications for membrane localization and cAMP signaling. Arch Biochem Biophys. 2006 Feb 1; 446(1):60-8.
|
|
|
|
|
58.
|
Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res. 2005 May 1; 11(9):3465-74.
|
|
|
|
|
59.
|
Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004 Oct 1; 64(19):7002-10.
|
|
|
|
|
60.
|
Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther. 2003 Nov; 307(2):468-75.
|
|
|
|
|
61.
|
Reiter CE, Sandirasegarane L, Wolpert EB, Klinger M, Simpson IA, Barber AJ, Antonetti DA, Kester M, Gardner TW. Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol Endocrinol Metab. 2003 Oct; 285(4):E763-74.
|
|
|
|
|
62.
|
Kester M, Kolesnick R. Sphingolipids as therapeutics. Pharmacol Res. 2003 May; 47(5):365-71.
|
|
|
|
|
63.
|
Yun JK, Kester M. Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. Arch Biochem Biophys. 2002 Dec 1; 408(1):78-86.
|
|
|
|
|
64.
|
Bourbon NA, Sandirasegarane L, Kester M. Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. J Biol Chem. 2002 Feb 1; 277(5):3286-92.
|
|
|
|
|
65.
|
Sandirasegarane L, Kester M. Enhanced stimulation of Akt-3/protein kinase B-gamma in human aortic smooth muscle cells. Biochem Biophys Res Commun. 2001 Apr 27; 283(1):158-63.
|
|
|
|
|
66.
|
Kester M, Waybill P, Kozak M. New strategies to prevent restenosis. Am J Cardiovasc Drugs. 2001; 1(2):77-83.
|
|
|
|
|
67.
|
Charles R, Sandirasegarane L, Yun J, Bourbon N, Wilson R, Rothstein RP, Levison SW, Kester M. Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries. Circ Res. 2000 Aug 18; 87(4):282-8.
|
|
|
|
|
68.
|
Sandirasegarane L, Charles R, Bourbon N, Kester M. NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest. Am J Physiol Cell Physiol. 2000 Jul; 279(1):C225-35.
|
|
|
|
|
69.
|
Marx SJ, Agarwal SK, Heppner C, Kim YS, Kester MB, Goldsmith PK, Skarulis MC, Spiegel AM, Burns AL, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Emmert-Buck MR, Guru SC, Manickam P, Crabtree JS, Collins FS, Chandrasekharappa SC. The gene for multiple endocrine neoplasia type 1: recent findings. Bone. 1999 Jul; 25(1):119-22.
|
|
|
|
|
70.
|
Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY, Spiegel AM, Burns AL, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Emmert-Buck MR, Guru SC, Manickam P, Crabtree J, Erdos MR, Collins FS, Chandrasekharappa SC. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res. 1999; 54:397-438; discussion 438-9.
|
|
|
|
|
71.
|
Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Emmert-Buck MR, Debelenko LV, Lubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE, Skarulis MC, Doppman JL, Alexander RH, Liotta LA, Collins FS, Chandrasekharappa SC, Spiegel AM, Burns AL. Germline and somatic mutation of the gene for multiple endocrine neoplasia type 1 (MEN1). J Intern Med. 1998 Jun; 243(6):447-53.
|
|
|
|
|
72.
|
Agarwal SK, Debelenko LV, Kester MB, Guru SC, Manickam P, Olufemi SE, Skarulis MC, Heppner C, Crabtree JS, Lubensky IA, Zhuang Z, Kim YS, Chandrasekharappa SC, Collins FS, Liotta LA, Spiegel AM, Burns AL, Emmert-Buck MR, Marx SJ. Analysis of recurrent germline mutations in the MEN1 gene encountered in apparently unrelated families. Hum Mutat. 1998; 12(2):75-82.
|
|
|
|
|
73.
|
Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE, Chandrasekharappa SC, Crabtree JS, Kim YS, Heppner C, Burns AL, Spiegel AM, Marx SJ, Liotta LA, Collins FS, Travis WD, Emmert-Buck MR. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997 Dec; 6(13):2285-90.
|
|
|
|
|
74.
|
Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC, Manickam P, Olufemi SE, Skarulis MC, Doppman JL, Alexander RH, Kim YS, Saggar SK, Lubensky IA, Zhuang Z, Liotta LA, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet. 1997 Aug; 16(4):375-8.
|
|
|
|
|
75.
|
Guru SC, Agarwal SK, Manickam P, Olufemi SE, Crabtree JS, Weisemann JM, Kester MB, Kim YS, Wang Y, Emmert-Buck MR, Liotta LA, Spiegel AM, Boguski MS, Roe BA, Collins FS, Marx SJ, Burns L, Chandrasekharappa SC. A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res. 1997 Jul; 7(7):725-35.
|
|
|
|
|
76.
|
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, Doppman JL, Kim YS, Lubensky IA, Zhuang Z, Green JS, Guru SC, Manickam P, Olufemi SE, Liotta LA, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997 Jul; 6(7):1169-75.
|
|
|
|
|
77.
|
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997 Apr 18; 276(5311):404-7.
|
|
|
|
|
78.
|
Sokolove PM, Kester MB, Westphal PA. Duramycin effects on the structure and function of heart mitochondria. II. Energy conversion reactions. Arch Biochem Biophys. 1991 May 15; 287(1):180-5.
|
|
|
|
|
79.
|
Kester MB, Sokolove PM. The effect of adriamycin and duramycin on calcium translocation in liposome systems modeled on the inner mitochondrial membrane. Arch Biochem Biophys. 1990 Aug 1; 280(2):405-11.
|
|
|
|